Press Releases

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will...

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has...

Symposium hosted by Eric S. Winer, MD, and Grzegorz S. Nowakowski, MD Updated data for 10 evaluable patients in Curis's PCNSL study Experts will present at the virtual meeting, free and open to...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer,...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer,...

EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer,...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on July 1, 2024,...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2024, the independent...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...

Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2024, the independent...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, last night presented clinical data...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company along...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered...

Continued progress on the development of emavusertib Strong balance sheet with $68.5 million in cash and investments; cash runway into 2025 Management to host conference call today at 8:30 a.m. ET...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies,...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 2, 2023, the independent...

Symposium hosted by Guillermo Garcia-Manero, M.D. and Eric Winer, M.D. Academics and industry professionals will gather virtually on September 22, 2023 LEXINGTON, Mass., Sept. 12, 2023...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies,...

Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies,...

Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment...

Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, today...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Board of Directors of Curis approved...

Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3 Curis strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.D. as Chief...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on March 31, 2023, the independent...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...

Curis completes enrollment of the 9 additional patients requested by FDA ahead of schedule in its TakeAim Leukemia study Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.,...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it is rescheduling its fourth quarter...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth...

29% CR rate observed in R/R AML patients with FLT3 mutation 22% CR/CRh rate observed in R/R AML with spliceosome mutation 45% ORR observed in R/R hrMDS patients with spliceosome mutation Curis to...

Curis to review results during conference call, featuring commentary by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET LEXINGTON, Mass., Dec. 5, 2022...

Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022 Curis focuses its resources to drive the development of emavusertib Cash runway extended...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company along with its collaborative...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 3, 2022, the independent...

Symposium hosted by Guillermo Garcia-Manero, M.D.; Hagop Kantarjian, M.D.; Amit Verma, M.B.B.S. Academics and industry professionals will gather virtually on October 7, 2022 LEXINGTON, Mass., Oct....

Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle, Ph.D. LEXINGTON, Mass., Sept. 19, 2022 /PRNewswire/ -- Curis, Inc....

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...

Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass., Aug. 30, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology...